CellaVision Boosts Profitability and Expands Digital Microscopy Footprint

The latest update is out from CellaVision AB ( (SE:CEVI) ).

CellaVision reported rising net sales from SEK 723 million to SEK 759 million and an EBITDA increase from SEK 219 million to SEK 241 million, with the EBITDA margin improving from 30% to 32%, underscoring continued profitable growth. During the period, the company launched new offerings including CellaVision Proficiency Software and the Sysmex DI-60™, secured CE marking under the EU IVDR for its Bone Marrow Aspirate application, acquired RAL Diagnostics and a Fourier Ptychographic Microscopy patent portfolio, and strengthened its long-standing innovation trajectory in digital microscopy and sample preparation.

These strategic moves deepen CellaVision’s integration across the hematology workflow, from sample preparation to advanced imaging and training, bolstering its position as a global leader in digital microscopy. The alliance with Sysmex, the acquisition of RAL Diagnostics, and the expansion into FPM technology collectively enhance the company’s technology base and market reach, supporting better laboratory efficiency and patient care while reinforcing its status on the NASDAQ Stockholm Mid Cap market.

The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK158.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.

More about CellaVision AB

CellaVision AB is a Swedish medical technology company specializing in digital microscopy for hematology and related laboratory diagnostics. Its primary products include automated cell morphology analyzers, proficiency and training software, and applications such as bone marrow aspirate analysis, with a market focus on improving workflow and diagnostic quality in clinical laboratories worldwide.

Average Trading Volume: 36,880

Technical Sentiment Signal: Sell

Current Market Cap: SEK3.59B

Learn more about CEVI stock on TipRanks’ Stock Analysis page.